当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い

オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得

インデックス付き
  • 索引コペルニクス
  • Google スカラー
  • Jゲートを開く
  • Genamics JournalSeek
  • 中国国家知識基盤 (CNKI)
  • 電子ジャーナルライブラリ
  • レフシーク
  • ハムダード大学
  • エブスコ アリゾナ州
  • OCLC-WorldCat
  • 仮想生物学図書館 (vifabio)
  • パブロン
  • ジュネーブ医学教育研究財団
  • ユーロパブ
  • ICMJE
このページをシェアする

抽象的な

Clinical Impact of the AKT1 rs1130233 SNP in Japanese Gastrointestinal Cancer Patients with Palliative Care

Takuto Morishita, Asahi Hishida, Yoshinaga Okugawa, Yuuki Morimoto, Yumiko Shirai, Kyoko Okamoto, Aki Ogawa, Koji Tanaka, Ryutaro Nishikawa, Yuji Toiyama, Yasuhiro Inoue, Hiroyuki Sakurai, Hisashi Urata, Motoyoshi Tanaka and Chikao Miki

Objective: Cancer patients often suffer from chronic inflammation, anorexia and the resultant decrease of nutrient intake, followed by weight loss and muscle wasting called “sarcopenia”. Such conditions are known as “cachexia”. In this study, we examined the associations between genetic polymorphisms of AKT1 rs1130233, ICAM1 rs281432, SELP rs6128 and TNSRSF1A rs4149570, which are reportedly associated with cachexia in Caucasians, together with LIF rs929271, in Japanese gastrointestinal cancer patients with palliative care. Methods: The study subjects were 59 patients (37 males and 22 females) with gastrointestinal cancers who visited the outpatient clinic at Iga General Hospital from December 2011 till August 2015. Genotypings for AKT1 rs1130233, ICAM1 rs281432, SELP rs6128, TNSRSF1A rs4149570 and LIF rs929271 were conducted with polymerase chain reaction with confronting two-pair primers (PCR-CTPP) or the Taqman SNP Genotyping assay. Associations of these SNPs with patients’ prognosis as well as weight loss defined as weight loss more than 5 percent during 6 months after the initiation of chemotherapy were evaluated. Results: A significant increase in the risk of 5% weight loss was observed in those with A/G genotype AKT1 rs1130233 polymorphism (AKT1 A/G vs. G/G, adjusted odds ratio [aOR]=7.11; 95%CI: 1.41-35.7), or in those with at least one A allele of AKT1 rs1130233 (AKT1 A/G+A/A vs. G/G, aOR=4.57; 95% CI: 1.14-18.3) when adjusted for age, sex and UICC clinical stage 4. There was no statistically significant correlation of the polymorphisms examined with patients’ survival. Conclusion: The present study revealed that AKT1 rs1130233 A allele may play a key role in the development of cancer cachexia. Given the involvement of AKT1 in the development of cancer as well as in apoptosis, it would be worth studying the roles of this molecule in human cancers further from clinical, epidemiological and biological viewpoints in the near future.

免責事項: この要約は人工知能ツールを使用して翻訳されており、まだレビューまたは確認されていません。